ASCENDIS PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 135.8 USD | +4.95% |
|
+10.23% | +7.81% |
| 06-25 | European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading | MT |
| 06-25 | TD Cowen Upgrades Ascendis Pharma to Buy Rating With $175 Price Target | MT |
Presenter SpeechKyuwon Choi (Analysts)Good morning, and welcome to day 2 of the Goldman Sachs ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
126.9
EUR
Average target price
170.7
EUR
Spread / Average Target
+34.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.81% | 7.79B | |
| +16.45% | 122B | |
| +21.96% | 116B | |
| +25.41% | 27.03B | |
| -20.05% | 20.36B | |
| -16.28% | 15.91B | |
| -15.96% | 16.43B | |
| -44.35% | 15.6B | |
| +63.91% | 14.94B | |
| +2.52% | 13.59B |
- Stock Market
- Equities
- ASND Stock
- News Ascendis Pharma A/S
- Transcript : Ascendis Pharma A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08
